Literature DB >> 8261466

Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.

C de Ines1, D Leynadier, I Barasoain, V Peyrot, P Garcia, C Briand, G A Rener, C Temple.   

Abstract

CI 980 (NSC 613862; [S-(-)]) and NSC 613863 [R-(+)] are the two chiral isomers of ethyl 5-amino 1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-ylcar bamate (NSC 370147), which is a mitotic inhibitor with in vivo and in vitro activity against murine multidrug-resistant sublines. We have characterized the inhibition of in vitro microtubule assembly by the S (CI 980) and R (NSC 613863) enantiomers, their actions on the cytoplasmic microtubule network of epithelial-like PtK2 cells, and on the cell cycle of different human and murine leukemias and PtK2 cells. Assembly of purified tubulin, or tubulin plus microtubule-associated proteins, into microtubules was substoichiometrically inhibited by both compounds, which also induced a slow depolymerization of preassembled microtubules. Half inhibitory concentrations were 0.4-0.7 microM and 1.6-2.1 microM for the S and R isomers, respectively. Excess of both drugs induced polymerization of liganded tubulin into abnormal polymers similar to colchicine. The cytoplasmic microtubules of PtK2 cells were disrupted by both compounds in a concentration- and time-dependent manner, which was observed by indirect immunofluorescence microscopy and quantified by an enzyme-linked immunoassay of cytoskeletal tubulin. Half inhibitory concentrations were 6 nM S isomer, 100 nM R isomer, and 1 microM colchicine. Twenty nM S isomer or 500-700 nM R isomer gave nearly maximal effect. At these concentrations, half maximal microtubule depolymerization took place after 2 h of treatment. After drug removal, slow microtubule assembly and nearly complete reorganization of the cytoplasmic microtubules of PtK2 cells were observed (24 h). One nM S enantiomer or 25 nM R enantiomer induced mitotic arrest in 8 h in U937, HL60, and EL4 leukemias. PtK2 cells also stopped in mitosis after a 24-h incubation with 50 nM R isomer or 5 nM S isomer. The inhibition of cell division was irreversible in the leukemic cells, while PtK2 cells partially resumed growth. Although the interactions of CI 980 with microtubules in vitro are not very different from other drugs, it is a most potent cellular microtubule and mitotic inhibitor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8261466

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Cellular transport of CI-980.

Authors:  K E Hook; S A Przybranowski; W R Leopold
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers.

Authors:  Pascale Barbier; Audrey Dorléans; Francois Devred; Laura Sanz; Diane Allegro; Carlos Alfonso; Marcel Knossow; Vincent Peyrot; Jose M Andreu
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

Review 3.  An overview of tubulin inhibitors that interact with the colchicine binding site.

Authors:  Yan Lu; Jianjun Chen; Min Xiao; Wei Li; Duane D Miller
Journal:  Pharm Res       Date:  2012-07-20       Impact factor: 4.200

4.  CI-980 in advanced melanoma and hormone refractory prostate cancer.

Authors:  C W Ryan; K L Shulman; J M Richards; J W Kugler; J A Sosman; R H Ansari; E E Vokes; N J Vogelzang
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

Review 5.  Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Authors:  M Smith; P T Ho
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

6.  Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.

Authors:  R P Whitehead; J M Unger; L E Flaherty; J R Eckardt; S A Taylor; M S Didolkar; W Samlowski; V K Sondak
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

7.  Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.

Authors:  S R Patel; M A Burgess; N E Papadopolous; G Sidhu; R Gray; C Plager; J Jenkins; R S Benjamin
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 8.  Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?

Authors:  Daniele Fanale; Giuseppe Bronte; Francesco Passiglia; Valentina Calò; Marta Castiglia; Florinda Di Piazza; Nadia Barraco; Antonina Cangemi; Maria Teresa Catarella; Lavinia Insalaco; Angela Listì; Rossella Maragliano; Daniela Massihnia; Alessandro Perez; Francesca Toia; Giuseppe Cicero; Viviana Bazan
Journal:  Anal Cell Pathol (Amst)       Date:  2015-09-21       Impact factor: 2.916

9.  The colchicine derivative CT20126 shows a novel microtubule-modulating activity with apoptosis.

Authors:  Sung-Kuk Kim; Sang-Min Cho; Ho Kim; Heon Seok; Soon-Ok Kim; Taeg Kyu Kwon; Jong-Soo Chang
Journal:  Exp Mol Med       Date:  2013-04-19       Impact factor: 8.718

10.  Characterisation of a navelbine-resistant bladder carcinoma cell line cross-resistant to taxoids.

Authors:  V Debal; N Allam; H Morjani; J M Millot; D Braguer; F Breillout; M Manfait
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.